Abstract
Purpose: To study the effectiveness of exogenous erythropoietin (EPO) against chronic heart failure (CHF) with anemia, and its effect on serum hypersensitive C reaction protein (hs-CRP), homocysteic acid (Hcy ) and B-type natriuretic peptide (BNP).Methods: A total of 136 patients suffering from CHF with anemia from June 2015 to June 2017 were randomly divided into observation group (n = 68) and control group (n = 68). On the basis of conventional anti-heart failure therapy, the control group received oral ferrous sulfate tablets, while the observation group received oral ferrous sulfate tablets combined with EPO subcutaneous injection. Blood indices, cardiac function and serology were determined and tested in all patients before treatment, and at 4 months after treatment.Results: After treatment, hemoglobin (Hb), hematocrit (HCT), red blood cell (RBC), blood platelet count (PLT) and serum iron were significantly higher than those before treatment in the two groups; the levels in the observation group were significantly higher than those in control group (p <0.05). Following treatment, left ventricular ejection fraction (LVEF), and 6-minute walking distance in the observation group were significantly higher than those in the control group, while end-diastolic dimension (LVEDD), end-systolic dimension (LVESD) and cardiac functional grading in the observation group were significantly lower than those in the control group (p < 0.05). After treatment, hs-CRP, Hcy and BNP were significantly lower than pre-treatment values in the two groups, while the values for the observation group were significantly lower than those of control group (p <0.05). Correlation analysis showed that LVEF and Hb were negatively correlated with hs-CRP, Hcy and BNP (p <0.05).Conclusion: Serum hs-CRP, Hcy and BNP are involved in the occurrence and progression of CHF with anemia. Exogenous EPO can effectively improve anemia and cardiac function in these patients.Keywords: Erythropoietin, Chronic heart failure, Anemia, C-reaction protein, B-type natriuretic peptide
Highlights
Chronic heart failure (CHF) is a common clinical cardiovascular disease which often occurs in middle-aged or elderly people, with serious effects on quality of life
The results of this study showed that after treatment, the levels of Hb, HCT, red blood cell (RBC), platelet count (PLT) and serum iron in the observation group were significantly higher than those in the control group, indicating that EPO adjuvant therapy can effectively improve anemia situation of patients with CHF combined with anemia
The results of the present study showed that cardiac function indices i.e. left ventricular ejection fraction (LVEF), LVEDD, LVESD, cardiac function grading, and 6-min walking distance in the observation group after treatment were significantly higher than corresponding values in the control group, indicating that EPO adjuvant therapies can improve clinical outcomes in patients with CHF and anemia
Summary
Chronic heart failure (CHF) is a common clinical cardiovascular disease which often occurs in middle-aged or elderly people, with serious effects on quality of life. It manifests in changes in cardiac structure and function due to primary cardiomyopathy, cardiac volume overload or long. CHF patients with anemia were treated by exogenouslysupplemented erythropoietin, and changes in serum levels of hs-CRP, Hcy and BNP were determined before and after treatment This was aimed at studying the clinical effectiveness and mechanisms of action of erythropoietin in the treatment of CHF patients with anemia so as to provide a new theoretical basis for treatment of this disease
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
